Cardiovascular risk reduction with glucagon-like peptide-1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta-regression analysis incorporating FLOW and SOUL trials.

Across the individual MACE components, although they did not reach statistical significance, directionally consistent relationships were observed: cardiovascular death (slope = −0.26; 95% CI: −0.72 to 0.19; p = 0.22), MI (slope = −0.26; 95% CI: −0.69 to 0.17; p = 0.20), and stroke (slope = −0.22; 95% CI: −0.80 to 0.36; p = 0.40) (Figure 3A–C ).

also in 111,027 other papers